On March 19, 2026, Arrowhead Pharmaceuticals, Inc. reported the outcomes of its Annual Meeting where seven directors were elected, the Amended and Restated 2021 Incentive Plan was approved, but the advisory executive compensation proposal was rejected; 119,801,542 shares were voted, with notable support for the directors and the incentive plan, while a majority opposed the executive compensation.